Monday, December 12, 2022 Caption: This transmission electron micrograph shows SARS-CoV-2 virus particles isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. In their continuous quest to improve COVID-19 vaccines, NIAID scientists have published two studies showing the potential benefits of single-dose nasal vaccines to prevent severe disease in children and adults. One vaccine candidate, based on a weakened avian paramyxovirus type 3 (APMV3), successfully protected hamsters from COVID-19. They next plan to test the vaccine in rhesus macaques. The second vaccine uses a weakened version of a bovine/human parainfluenza virus (B/HPIV3) to deliver the SARS-CoV-2 spike protein into the respiratory tract. In that project, the scientists used the vaccine to protect rhesus macaques from COVID-19. Their vaccine produced a strong immune response to the SARS-CoV-2 spike protein in the respiratory tract, protecting the areas where the virus first infects people. They plan to proceed to a Phase 1 clinical trial testing the vaccine as a nasal spray in volunteers. Prior to the COVID-19 pandemic, a version of the B/HPIV3 vaccine (without the SARS-CoV-2 spike) had been in studies to prevent respiratory illness caused by human parainfluenza virus type 3 (HPIV3) in young children.  |
No comments:
Post a Comment